THE INVESTOR

메뉴열기
September 20, 2020

Enzychem Lifesciences’ COVID-19 drug proceeds to phase 2 trial

PUBLISHED : August 07, 2020 - 15:53

UPDATED : August 07, 2020 - 15:53

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

Enzychem Lifesciences’ COVID-19 treatment candidate EC-18 was granted by the US’ Food and Drug Administration to carry out phase 2 clinical trial on confirmed patients, the company said on August 7.

In this phase 2 clinical trial, Enzychem Lifesciences will confirm the therapeutic effects of EC-18 for acute respiratory distress syndrome prevalent in COVID-19 patients with pneumonia.



EC-18 is a novel drug candidate that had been in phase 2 clinical trials for chemoradiation-induced oral muscositis, chemotherapy induced complications such as neutropenia and acute radiation syndrome.

The drug is being tested to repurpose as COVID-19 treatment. Korean drug authorities have also given the approval for the drug to proceed to a phase 2 clinical trial here.

Enzychem Lifesciences’ phase 2 test design will target 60 COVID-19 patients, of whom 30 will be given the standard treatment with EC-18, while the rest will be given standard treatment with placebo.

Enzychem Lifesciences is listed on Korea’s secondary bourse, Kosdaq.

By Lim Jeong-yeo (kaylalim@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.